Tekla Life Sciences Stock Current Valuation
| HQL Stock | USD 14.13 0.21 1.51% |
Valuation analysis of Tekla Life Sciences helps investors to measure Tekla Life's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Tekla Life's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 14.12 this year, although Enterprise Value will most likely fall to about 233 M. Fundamental drivers impacting Tekla Life's valuation include:
Price Book 0.8762 | Enterprise Value 370.8 M | Price Sales 110.0118 | Trailing PE 10.5448 | Enterprise Value Revenue 9.6735 |
Fairly Valued
Today
Please note that Tekla Life's price fluctuation is very steady at this time. Calculation of the real value of Tekla Life Sciences is based on 3 months time horizon. Increasing Tekla Life's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tekla stock is determined by what a typical buyer is willing to pay for full or partial control of Tekla Life Sciences. Since Tekla Life is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tekla Stock. However, Tekla Life's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.13 | Real 14.13 | Hype 14.13 |
The intrinsic value of Tekla Life's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Tekla Life's stock price.
Estimating the potential upside or downside of Tekla Life Sciences helps investors to forecast how Tekla stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tekla Life more accurately as focusing exclusively on Tekla Life's fundamentals will not take into account other important factors: Tekla Life Sciences Company Current Valuation Analysis
Tekla Life's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tekla Life Current Valuation | 370.8 M |
Most of Tekla Life's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tekla Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tekla Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Tekla Life is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Current Valuation. Since Tekla Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Tekla Life Sciences has a Current Valuation of 370.8 M. This is 98.87% lower than that of the Capital Markets sector and 95.04% lower than that of the Financials industry. The current valuation for all United States stocks is 97.77% higher than that of the company.
Tekla Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tekla Life's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tekla Life could also be used in its relative valuation, which is a method of valuing Tekla Life by comparing valuation metrics of similar companies.Tekla Life is currently under evaluation in current valuation category among its peers.
Tekla Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Life's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Tekla Fundamentals
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 1.56 % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 370.8 M | ||||
| Shares Outstanding | 27.35 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 35.35 % | ||||
| Number Of Shares Shorted | 74.12 K | ||||
| Price To Earning | 2.84 X | ||||
| Price To Book | 0.88 X | ||||
| Price To Sales | 110.01 X | ||||
| Revenue | 23.52 M | ||||
| Gross Profit | 3.02 M | ||||
| EBITDA | 22.35 M | ||||
| Net Income | 22.35 M | ||||
| Cash And Equivalents | 292.4 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 666.96 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 16.13 X | ||||
| Cash Flow From Operations | (12.8 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | 1.34 X | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 386.46 M | ||||
| Total Asset | 402.6 M | ||||
| Retained Earnings | (1.48 M) | ||||
| Annual Yield | 0.14 % | ||||
| Five Year Return | 8.83 % | ||||
| Net Asset | 402.6 M | ||||
| Last Dividend Paid | 1.3 |
About Tekla Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tekla Life Piotroski F Score and Tekla Life Altman Z Score analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.